Molecular mechanisms of acquired proteasome inhibitor resistance

Journal of Medicinal Chemistry

Volumn 55, Issue 23, 2012, Pages 10317-10327

  Kale, Andrew J ^a   Moore, Bradley S ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DELANZOMIB; OPROZOMIB; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UBIQUITIN;

CANCER CELL CULTURE; CANCER THERAPY; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; REVIEW;

ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; UP-REGULATION;

EID: 84871020567     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300434z     Document Type: Review

References (65)

1. Murata, S.; Yashiroda, H.; Tanaka, K. Molecular mechanisms of proteasome assembly Nat. Rev. Mol. Cell Biol. 2009, 10, 104-115
2. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development Chem. Rev. 2007, 107, 687-717
3. Genin, E.; Reboud-Ravaux, M.; Vidal, J. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry Curr. Top. Med. Chem. 2010, 10, 232-256
4. Nencioni, A.; Grunebach, F.; Patrone, F.; Ballestrero, A.; Brossart, P. Proteasome inhibitors: antitumor effects and beyond Leukemia 2007, 21, 30-36
5. Woodle, E. S.; Walsh, R. C.; Alloway, R. R.; Girnita, A.; Brailey, P. Proteasome inhibitor therapy for antibody-mediated rejection Pediatr. Transplant. 2011, 15, 548-556
6. Kisselev, A. F.; van der Linden, W. A.; Overkleeft, H. S. Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 2012, 19, 99-115
7. Cheriyath, V.; Jacobs, B. S.; Hussein, M. A. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors Drugs R&D 2007, 8, 1-12
8. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade Clin. Cancer. Res. 2008, 14, 1649-1657
9. McConkey, D. J.; Zhu, K. Mechanisms of proteasome inhibitor action and resistance in cancer Drug Resist. Updates 2008, 11, 164-179
10. Naujokat, C.; Hoffmann, S. Role and function of the 26S proteasome in proliferation and apoptosis Lab. Invest. 2002, 82, 965-980
11. Fuchs, D.; Berges, C.; Opelz, G.; Daniel, V.; Naujokat, C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells J. Cell. Biochem. 2008, 103, 270-283
12. Oerlemans, R.; Franke, N. E.; Assaraf, Y. G.; Cloos, J.; van Zantwijk, I.; Berkers, C. R.; Scheffer, G. L.; Debipersad, K.; Vojtekova, K.; Lemos, C.; van der Heijden, J. W.; Ylstra, B.; Peters, G. J.; Kaspers, G. L.; Dijkmans, B. A. C.; Scheper, R. J.; Jansen, G. Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood. 2008, 112, 2489-2499
13. Lü, S. Q.; Yang, J. M.; Song, X. M.; Gong, S. L.; Zhou, H.; Guo, L. P.; Song, N. X.; Bao, X. C.; Chen, P. P.; Wang, J. M. Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line J. Pharmacol. Exp. Ther. 2008, 326, 423-431
14. Lü, S. Q.; Yang, J. M.; Chen, Z. L.; Gong, S. L.; Zhou, H.; Xu, X. Q.; Wang, J. M. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line Exp. Hematol. 2009, 37, 831-837
15. Rückrich, T.; Kraus, M.; Gogel, J.; Beck, A.; Ovaa, H.; Verdoes, M.; Overkleeft, H. S.; Kalbacher, H.; Driessen, C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells Leukemia 2009, 23, 1098-1105
16. Ri, M.; Iida, S.; Nakashima, T.; Miyazaki, H.; Mori, F.; Ito, A.; Inagaki, A.; Kusumoto, S.; Ishida, T.; Komatsu, H.; Shiotsu, Y.; Ueda, R. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress Leukemia 2010, 24, 1506-1512
17. Pérez-Galán, P.; Mora-Jensen, H.; Weniger, M. A.; Shaffer, A. L.; Rizzatti, E. G.; Chapman, C. M.; Mo, C. C.; Stennett, L. S.; Rader, C.; Liu, P. C.; Raghavachari, N.; Stetler-Stevenson, M.; Yuan, C.; Pittaluga, S.; Maric, I.; Dunleavy, K. M.; Wilson, W. H.; Staudt, L. M.; Wiestner, A. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation Blood 2011, 117, 542-552
18. Franke, N. E.; Niewerth, D.; Assaraf, Y. G.; van Meerloo, J.; Vojtekova, K.; van Zantwijk, C. H.; Zweegman, S.; Chan, E. T.; Kirk, C. J.; Geerke, D. P.; Schimmer, A. D.; Kaspers, G. J. L.; Jansen, G.; Cloos, J. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells Leukemia 2011, 26, 757-768
19. Suzuki, E.; Demo, S.; Deu, E.; Keats, J.; Arastu-Kapur, S.; Bergsagel, P. L.; Bennett, M. K.; Kirk, C. J. Molecular mechanisms of bortezomib resistant adenocarcinoma cells PLoS One 2011, 6, e27996
20. de Wilt, L. H. A. M.; Jansen, G.; Assaraf, Y. G.; van Meerloo, J.; Cloos, J.; Schimmer, A. D.; Chan, E. T.; Kirk, C. J.; Peters, G. J.; Kruyt, F. A. E. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer Biochem. Pharmacol. 2012, 83, 207-217
21. Balsas, P.; Galan-Malo, P.; Marzo, I.; Naval, J. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy Leuk. Res. 2012, 36, 212-218
22. Finley, D. Recognition and processing of ubiquitin-protein conjugates by the proteasome Annu. Rev. Biochem. 2009, 78, 477-513
23. Xu, G. W.; Ali, M.; Wood, T. E.; Wong, D.; Maclean, N.; Wang, X. M.; Gronda, M.; Skrtic, M.; Li, X. M.; Hurren, R.; Mao, X. L.; Venkatesan, M.; Zavareh, R. B.; Ketela, T.; Reed, J. C.; Rose, D.; Moffat, J.; Batey, R. A.; Dhe-Paganon, S.; Schimmer, A. D. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma Blood 2010, 115, 2251-2259
24. Hochstrasser, M. Origin and function of ubiquitin-like proteins Nature 2009, 458, 422-429
25. Groll, M.; Bochtler, M.; Brandstetter, H.; Clausen, T.; Huber, R. Molecular machines for protein degradation ChemBioChem 2005, 6, 222-256
26. Darwin, K. H.; Ehrt, S.; Gutierrez-Ramos, J. C.; Weich, N.; Nathan, C. F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide Science 2003, 302, 1963-1966
27. Imajoh-Ohmi, S.; Kawaguchi, T.; Sugiyama, S.; Tanaka, K.; Omura, S.; Kikuchi, H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells Biochem. Biophys. Res. Commun. 1995, 217, 1070-1077
28. Delic, J.; Masdehors, P.; Omura, S.; Cosset, J. M.; Dumont, J.; Binet, J. L.; Magdelenat, H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis Br. J. Cancer 1998, 77, 1103-1107
29. Orlowski, R. Z.; Eswara, J. R.; Lafond-Walker, A.; Grever, M. R.; Orlowski, M.; Dang, C. V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor Cancer Res. 1998, 58, 4342-4348
30. Hideshima, T.; Richardson, P. G.; Anderson, K. C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma Mol. Cancer Ther. 2011, 10, 2034-2042
31. Masdehors, P.; Merle-Beral, H.; Maloum, K.; Omura, S.; Magdelenat, H.; Delic, J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes Blood 2000, 96, 269-274
32. Bianchi, G.; Oliva, L.; Cascio, P.; Pengo, N.; Fontana, F.; Cerruti, F.; Orsi, A.; Pasqualetto, E.; Mezghrani, A.; Calbi, V.; Palladini, G.; Giuliani, N.; Anderson, K. C.; Sitia, R.; Cenci, S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition Blood 2009, 113, 3040-3049
33. Cenci, S.; Mezghrani, A.; Cascio, P.; Bianchi, G.; Cerruti, F.; Fra, A.; Lelouard, H.; Masciarelli, S.; Mattioli, L.; Oliva, L.; Orsi, A.; Pasqualetto, E.; Pierre, P.; Ruffato, E.; Tagliavacca, L.; Sitia, R. Progressively impaired proteasomal capacity during terminal plasma cell differentiation EMBO J. 2006, 25, 1104-1113
34. Moore, B. S.; Eustáquio, A. S.; McGlinchey, R. P. Advances in and applications of proteasome inhibitors Curr. Opin. Chem. Biol. 2008, 12, 434-440
35. Groll, M.; Nazif, T.; Huber, R.; Bogyo, M. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome Chem. Biol. 2002, 9, 655-662
36. Dick, L. R.; Fleming, P. E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy Drug Discovery Today 2010, 15, 243-249
37. Ruschak, A. M.; Slassi, M.; Kay, L. E.; Schimmer, A. D. Novel proteasome inhibitors to overcome bortezomib resistance J. Natl. Cancer Inst. 2011, 103, 1007-1017
38. Moreau, P.; Pylypenko, H.; Grosicki, S.; Karamanesht, I.; Leleu, X.; Grishunina, M.; Rekhtman, G.; Masliak, Z.; Robak, T.; Shubina, A.; Arnulf, B.; Kropff, M.; Cavet, J.; Esseltine, D. L.; Feng, H. B.; Girgis, S.; van de Velde, H.; Deraedt, W.; Harousseau, J. L. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol. 2011, 12, 431-440
39. Kupperman, E.; Lee, E. C.; Cao, Y. Y.; Bannerman, B.; Fitzgerald, M.; Berger, A.; Yu, J.; Yang, Y.; Hales, P.; Bruzzese, F.; Liu, J.; Blank, J.; Garcia, K.; Tsu, C.; Dick, L.; Fleming, P.; Yu, L.; Manfredi, M.; Rolfe, M.; Bolen, J. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer Cancer Res. 2010, 70, 1970-1980
40. Piva, R.; Ruggeri, B.; Williams, M.; Costa, G.; Tamagno, I.; Ferrero, D.; Giai, V.; Coscia, M.; Peola, S.; Massaia, M.; Pezzoni, G.; Allievi, C.; Pescalli, N.; Cassin, M.; di Giovine, S.; Nicoli, P.; de Feudis, P.; Strepponi, I.; Roato, I.; Ferracini, R.; Bussolati, B.; Camussi, G.; Jones-Bolin, S.; Hunter, K.; Zhao, H.; Neri, A.; Palumbo, A.; Berkers, C.; Ovaa, H.; Bernareggi, A.; Inghirami, G. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib Blood 2008, 111, 2765-2775
41. Demo, S. D.; Kirk, C. J.; Aujay, M. A.; Buchholz, T. J.; Dajee, M.; Ho, M. N.; Jiang, J.; Laidig, G. J.; Lewis, E. R.; Parlati, F.; Shenk, K. D.; Smyth, M. S.; Sun, C. M.; Vallone, M. K.; Woo, T. M.; Molineaux, C. J.; Bennett, M. K. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res. 2007, 67, 6383-6391
42. Zhou, H. J.; Aujay, M. A.; Bennett, M. K.; Dajee, M.; Demo, S. D.; Fang, Y.; Ho, M. N.; Jiang, J.; Kirk, C. J.; Laidig, G. J.; Lewis, E. R.; Lu, Y.; Muchamuel, T.; Parlati, F.; Ring, E.; Shenk, K. D.; Shields, J.; Shwonek, P. J.; Stanton, T.; Sun, C. C. M.; Sylvain, C.; Woo, T. M.; Yang, J. F. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047) J. Med. Chem. 2009, 52, 3028-3038
43. Roccaro, A. M.; Sacco, A.; Aujay, M.; Ngo, H. T.; Azab, A. K.; Azab, F.; Quang, P.; Maiso, P.; Runnels, J.; Anderson, K. C.; Demo, S.; Ghobrial, I. M. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia Blood 2010, 115, 4051-4060
44. Meng, L. H.; Mohan, R.; Kwok, B. H. B.; Elofsson, M.; Sin, N.; Crews, C. M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10403-10408
45. Gulder, T. A. M.; Moore, B. S. Salinosporamide natural products: potent 20S proteasome inhibitors as promising cancer chemotherapeutics Angew. Chem., Int. Ed. 2010, 49, 9346-9367
46. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D.-L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma N. Engl. J. Med. 2003, 348, 2609-2617
47. Shaughnessy, J. D.; Qu, P.; Usmani, S.; Heuck, C. J.; Zhang, Q.; Zhou, Y.; Tian, E.; Hanamura, I.; van Rhee, F.; Anaissie, E.; Epstein, J.; Nair, B.; Stephens, O.; Williams, R.; Waheed, S.; Alsayed, Y.; Crowley, J.; Barlogie, B. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3 Blood 2011, 118, 3512-3524
48. Kraus, M.; Rückrich, T.; Reich, M.; Gogel, J.; Beck, A.; Kammer, W.; Berkers, C. R.; Burg, D.; Overkleeft, H.; Ovaa, H.; Driessen, C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells Leukemia 2007, 21, 84-92
49. Groll, M.; Berkers, C. R.; Ploegh, H. L.; Ovaa, H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome Structure 2006, 14, 451-456
50. Kale, A. J.; McGlinchey, R. P.; Lechner, A.; Moore, B. S. Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A ACS Chem. Biol. 2011, 6, 1257-1264
51. Sharma, R. C.; Inoue, S.; Roitelman, J.; Schimke, R. T.; Simoni, R. D. Peptide transport by the multidrug resistance pump J. Biol. Chem. 1992, 267, 5731-5734
52. de Jong, M. C.; Slootstra, J. W.; Scheffer, G. L.; Schroeijers, A. B.; Puijk, W. C.; Dinkelberg, R.; Kool, M.; Broxterman, H. J.; Meloen, R. H.; Scheper, R. J. Peptide transport by the multidrug resistance protein MRP1 Cancer Res. 2001, 61, 2552-2557
53. Minderman, H.; Zhou, Y. F.; O'Loughlin, K. L.; Baer, M. R. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status Cancer Chemother. Pharmacol. 2007, 60, 245-255
54. Verbrugge, S. E.; Assaraf, Y. G.; Dijkmans, B. A. C.; Scheffer, G. L.; Al, M.; den Uyl, D.; Oerlemans, R.; Chan, E. T.; Kirk, C. J.; Peters, G. J.; Van der Heijden, J. W.; de Gruijl, T. D.; Scheper, R. J.; Jansen, G. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis J. Pharmacol. Exp. Ther. 2012, 341, 174-182
55. Politou, M.; Karadimitris, A.; Terpos, E.; Kotsianidis, I.; Apperley, J. F.; Rahemtulla, A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib Leuk. Res. 2006, 30, 240-241
56. Sanchez, E.; Li, M. J.; Steinberg, J. A.; Wang, C.; Shen, J.; Bonavida, B.; Li, Z. W.; Chen, H. M.; Berenson, J. R. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan Br. J. Haematol. 2010, 148, 569-581
57. Kuhn, D. J.; Chen, Q.; Voorhees, P. M.; Strader, J. S.; Shenk, K. D.; Sun, C. M.; Demo, S. D.; Bennett, M. K.; van Leeuwen, F. W. B.; Chanan-Khan, A. A.; Orlowski, R. Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 2007, 110, 3281-3290
58. Chauhan, D.; Singh, A. V.; Aujay, M.; Kirk, C. J.; Bandi, M.; Ciccarelli, B.; Raje, N.; Richardson, P.; Anderson, K. C. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma Blood 2010, 116, 4906-4915
59. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T.-H.; Neuteboom, S. T. C.; Richardson, P.; Palladino, M. A.; Anderson, K. C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib Cancer Cell 2005, 8, 407-419
60. Gao, Y. H.; Lecker, S.; Post, M. J.; Hietaranta, A. J.; Li, J.; Volk, R.; Li, M.; Sato, K.; Saluja, A. K.; Steer, M. L.; Goldberg, A. L.; Simons, M. Inhibition of ubiquitin-proteasome pathway-mediated IκBα degradation by a naturally occurring antibacterial peptide J. Clin. Invest. 2000, 106, 439-448
61. Li, J.; Post, M.; Volk, R.; Gao, Y.; Li, M.; Metais, C.; Sato, K.; Tsai, J.; Aird, W.; Rosenberg, R. D.; Hampton, T. G.; Li, J.; Sellke, F.; Carmeliet, P.; Simons, M. PR39, a peptide regulator of angiogenesis Nat. Med. 2000, 6, 49-55
62. Sprangers, R.; Li, X. M.; Mao, X. L.; Rubinstein, J. L.; Schimmer, A. D.; Kay, L. E. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors Biochemistry 2008, 47, 6727-6734
63. Li, X. M.; Wood, T. E.; Sprangers, R.; Jansen, G.; Franke, N. E.; Mao, X. L.; Wang, X. M.; Zhang, Y.; Verbrugge, S. E.; Adomat, H.; Li, Z. H.; Trudel, S.; Chen, C.; Religa, T. L.; Jamal, N.; Messner, H.; Cloos, J.; Rose, D. R.; Navon, A.; Guns, E.; Batey, R. A.; Kay, L. E.; Schimmer, A. D. Effect of noncompetitive proteasome inhibition on bortezomib resistance J. Natl. Cancer Inst. 2010, 102, 1069-1082
64. Edelmann, M. J.; Nicholson, B.; Kessler, B. M. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases Expert Rev. Mol. Med. 2011, 13, e35
65. The PyMOL Molecular Graphics System, version 1.5.0.1; Schrödinger, LLC: New York.